Summary
This prediction ended on 16.10.21 with a price of €41.41. With a performance of 721.46% the BUY prediction by sunnytrader was a big success. sunnytrader has 50% into this predictionEvotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Evotec SE | -3.233% | -3.233% | -64.983% | -84.780% |
iShares Core DAX® | -1.114% | 5.062% | 24.922% | 25.215% |
iShares Nasdaq 100 | 1.816% | 9.828% | 29.548% | 44.324% |
iShares Nikkei 225® | 2.113% | 8.218% | 22.231% | 12.395% |
iShares S&P 500 | 2.038% | 7.448% | 30.358% | 43.899% |
Comments by sunnytrader for this prediction
In the thread Evotec AG diskutieren
Evotec wird liefern
Am 10.11.2016 liegt die Quartalsmitteilung Q3 von Evotec vor.
Zur Zeit verteidigt das Papier immer erfolgreich die 5-Euro-Marke. Ich gehe davon aus, dass
bis Ende des Jahres diese deutsche Biotec-Perle die "6" anvisieren wird.
Einen nochmaligen Test der Marke 4,78/4,83 Euro nehme ich
in Kauf.